Anixa Biosciences Inc entered into Joint Development and Option Agreement with Cleveland Clinic Foundation valued at Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding (effective 2024-05-03).
“On May 3, 2024, Anixa Biosciences, Inc. (the “ Company ”) and the Cleveland Clinic Foundation (the “ CCF ”) entered into a Joint Development and Option Agreement (the “ Agreement ”). Pursuant to the Agreement, the parties agreed on the terms and conditions under which the parties will collaborate in efforts to develop vaccines for the prevention or treatment of cancers in the Fields.”
Shareholder Votes
Anixa Biosciences Inc shareholders approved Ratification of the appointment of independent registered public accounting firm at the 2024-03-21 meeting.
“The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 18,390,227 80,392 51,167 -”
Shareholder Votes
Anixa Biosciences Inc shareholders approved Approval, by non-binding advisory vote, of the Company's executive compensation at the 2024-03-21 meeting.
“The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 6,010,385 1,843,353 123,415 10,544,633”
Shareholder Votes
Anixa Biosciences Inc shareholders approved Election of directors at the 2024-03-21 meeting.
“The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote Dr. Amit Kumar 7,894,499 82,654 10,544,633 Dr. Arnold Baskies 7,857,006 120,147 10,544,633 Emily Gottschalk 7,853,085 124,068 10,544,633 Lewis H. Titterton, Jr. 7,718,162 258,991 10,544,633”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.